Hereditary thrombophilic risk factors for recurrent pregnancy loss

被引:21
作者
Bogdanova N. [1 ]
Markoff A. [2 ]
机构
[1] Institute of Human Genetics, Westfalian-Wilhelms University of Muenster, 48149 Münster
[2] Institute of Medical Biochemistry, ZMBE, Westfalian-Wilhelms University of Muenster, 48149 Münster
关键词
Fetal loss; Genetic predisposition; Recurrent pregnancy loss; Risk factors; Thrombophilia;
D O I
10.1007/s12687-010-0011-3
中图分类号
学科分类号
摘要
This review summarizes current knowledge about the role of hereditary hypercoagulation factors predisposing to thrombophilia-associated recurrent fetal loss. Thrombophilias are a major cause of adverse pregnancy outcome, playing a role in the etiology of up to 40% of cases worldwide. Hereditary thrombophilic predispositions to recurrent pregnancy wastage include genetic lesions in blood coagulation factors II and V as well as natural anticoagulants antithrombin, protein C, and protein S. Furthermore, methylenetetrahydrofolate reductase gene variants conferring higher thrombophilia risk in combination with these mutations and the newly described annexin A5 gene M2 promoter allele are associated with repeated fetal loss. The review gives a concise description of the molecular defects arising from the genetic changes, of the role these factors play in the timing and definition of fetal loss, and risk estimates from available studies and meta-analysis. This knowledge is instrumental for a more precise assessment of individual risks for repeated fetal loss and should guide therapeutic strategies, where relevant. Since the average childbearing age increases in Western societies, the importance of a timely diagnosis of fetal loss predisposition is increasing. © Springer-Verlag 2010.
引用
收藏
页码:47 / 53
页数:6
相关论文
共 65 条
[1]
Alfirevic Z., Kurjak A., Transvaginal colour Doppler ultrasound in normal and abnormal early pregnancy, Journal of Perinatal Medicine, 18, 3, pp. 173-180, (1990)
[2]
Bates S.M., Greer I.A., Pabinger I., Sofaer S., Hirsh J., Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition), Chest, 133, 6 SUPPL. 6, (2008)
[3]
Bertina R.M., Koeleman B.P.C., Koster T., Rosendaal F.R., Dirven R.J., De Ronde H., Van Der Velden P.A., Reitsma P.H., Mutation in blood coagulation factor V associated with resistance to activated protein C, Nature, 369, 6475, pp. 64-67, (1994)
[4]
Bick R.L., Recurrent miscarriage syndrome due to blood coagulation protein/platelet defects: Prevalence, treatment and outcome results, Clinical and Applied Thrombosis/Hemostasis, 6, 3, pp. 115-125, (2000)
[5]
Bogdanova N., Horst J., Chlystun M., Croucher P.J.P., Nebel A., Bohring A., Todorova A., Schreiber S., Gerke V., Krawczak M., Markoff A., A common haplotype of the annexin A5 (ANXA5) gene promoter is associated with recurrent pregnancy loss, Human Molecular Genetics, 16, 5, pp. 573-578, (2007)
[6]
Bosler D., Mattson J., Crisan D., Phenotypic heterogeneity in patients with homozygous prothrombin 20210AA genotype, J Mol Diagn, 4, pp. 420-425, (2006)
[7]
Branch D.W., Silver R.M., Blackwell J.L., Reading J.C., Scott J.R., Outcome of treated pregnancies in women with antiphospholipid syndrome: An update of the Utah experience, Obstet Gynecol, 80, pp. 614-620, (1992)
[8]
Brenner B., Sarig G., Weiner Z., Younis J., Blumenfeld Z., Lanir N., Thrombophilic polymorphisms are common in women with fetal loss without apparent cause, Thrombosis and Haemostasis, 82, 1, pp. 6-9, (1999)
[9]
Cattaneo M., Hyperhomocysteinemia, atherosclerosis and thrombosis, Thrombosis and Haemostasis, 81, 2, pp. 165-176, (1999)
[10]
Cattaneo M., Tsai M.Y., Bucciarelli P., Taioli E., Zighetti M.L., Bignell M., Mannucci P.M., A common mutation in the methylenetetrahydrofolate reductase gene (C677T) increases the risk for deep-vein thrombosis in patients with mutant factor V (factor V:Q<sup>506</sup>), Arteriosclerosis, Thrombosis, and Vascular Biology, 17, 9, pp. 1662-1666, (1997)